These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 29424441

  • 1. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
    Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI.
    Transfusion; 2018 Apr; 58(4):974-981. PubMed ID: 29424441
    [Abstract] [Full Text] [Related]

  • 2. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
    Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M.
    Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
    [Abstract] [Full Text] [Related]

  • 3. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B, Bhandari S, Barany P, Kalra PA, Ladefoged S, Wilske J, Thomsen LL.
    J Nephrol; 2011 Apr; 24(5):589-96. PubMed ID: 21240875
    [Abstract] [Full Text] [Related]

  • 4. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A, Bhandari S.
    Trials; 2019 Apr 04; 20(1):194. PubMed ID: 30947751
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
    Stein J, Walper A, Klemm W, Farrag K, Aksan A, Dignass A.
    Scand J Gastroenterol; 2018 Sep 04; 53(9):1059-1065. PubMed ID: 30222479
    [Abstract] [Full Text] [Related]

  • 6. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
    Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, Nijhawan S, Thomsen LL.
    Am J Gastroenterol; 2013 Dec 04; 108(12):1877-88. PubMed ID: 24145678
    [Abstract] [Full Text] [Related]

  • 7. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
    Charles-Edwards G, Amaral N, Sleigh A, Ayis S, Catibog N, McDonagh T, Monaghan M, Amin-Youssef G, Kemp GJ, Shah AM, Okonko DO.
    Circulation; 2019 May 21; 139(21):2386-2398. PubMed ID: 30776909
    [Abstract] [Full Text] [Related]

  • 8. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
    Bhandari S, Kalra PA, Kothari J, Ambühl PM, Christensen JH, Essaian AM, Thomsen LL, Macdougall IC, Coyne DW.
    Nephrol Dial Transplant; 2015 Sep 21; 30(9):1577-89. PubMed ID: 25925701
    [Abstract] [Full Text] [Related]

  • 9. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, Thomsen LL, Carpenter TO, Weber T, Brandenburg V, Zoller H.
    JAMA; 2020 Feb 04; 323(5):432-443. PubMed ID: 32016310
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
    Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M.
    Am J Hematol; 2017 Mar 04; 92(3):286-291. PubMed ID: 28052413
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
    Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW.
    Nephrol Dial Transplant; 2016 Apr 04; 31(4):646-55. PubMed ID: 26250435
    [Abstract] [Full Text] [Related]

  • 12. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.
    Kalra PA, Bhandari S, Spyridon M, Davison R, Lawman S, Mikhail A, Reaich D, Pritchard N, McCafferty K, Moore J.
    BMC Nephrol; 2020 Dec 10; 21(1):539. PubMed ID: 33302891
    [Abstract] [Full Text] [Related]

  • 13. Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial).
    Johansson PI, Rasmussen AS, Thomsen LL.
    Vox Sang; 2015 Oct 10; 109(3):257-66. PubMed ID: 25900643
    [Abstract] [Full Text] [Related]

  • 14. Intravenous iron isomaltoside 1000 administered by high single-dose infusions or standard medical care for the treatment of fatigue in women after postpartum haemorrhage: study protocol for a randomised controlled trial.
    Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J.
    Trials; 2015 Jan 14; 16():5. PubMed ID: 25588587
    [Abstract] [Full Text] [Related]

  • 15. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
    Dahlerup JF, Jacobsen BA, van der Woude J, Bark LÅ, Thomsen LL, Lindgren S.
    Scand J Gastroenterol; 2016 Nov 14; 51(11):1332-8. PubMed ID: 27326766
    [Abstract] [Full Text] [Related]

  • 16. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
.
    Jensen G, Gøransson LG, Fernström A, Furuland H, Christensen JH.
    Clin Nephrol; 2019 Apr 14; 91(4):246-253. PubMed ID: 30614439
    [Abstract] [Full Text] [Related]

  • 17. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer® ) versus ferric carboxy-maltose (Ferinject® ). A single center, cohort study.
    Mulder MB, van den Hoek HL, Birnie E, van Tilburg AJP, Westerman EM.
    Br J Clin Pharmacol; 2019 Feb 14; 85(2):385-392. PubMed ID: 30393904
    [Abstract] [Full Text] [Related]

  • 18. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia
.
    Biggar P, Leistikow F, Walper A.
    Clin Nephrol; 2016 Dec 14; 86 (2016)(12):310-318. PubMed ID: 27737531
    [Abstract] [Full Text] [Related]

  • 19. Iron (III) isomaltoside 1000.
    Mace TA, Syed A, Bhandari S.
    Expert Rev Hematol; 2013 Jun 14; 6(3):239-46. PubMed ID: 23782077
    [Abstract] [Full Text] [Related]

  • 20. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF, Muduma G.
    Expert Rev Hematol; 2019 Feb 14; 12(2):129-136. PubMed ID: 30689458
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.